Jacob Bell
New Member
Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy
Author(s) Sallan SE, Zinberg NE, Frei E 3d
Journal, Volume, Issue New England Journal of Medicine 1975;293(16):795-797
Major outcome(s) for patients completing the study there were 5 complete responses (no vomiting) and 7 partial responses (50% decrease of vomiting) of overall 15 courses
Indication Cancer chemotherapy; Nausea/vomiting
Medication Delta-9-THC
Route(s) Oral
Dose(s) 3 x 10 or 15 mg/m2 every 4 hours
Duration (days) several days
Participants 84 cancer patients
Design Controlled study
Type of publication
Address of author(s) Sidney Farber Cancer Center, Boston, Massachusetts, USA
Abstract
Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents. Oral delta-9-tetrahydrocannabinol was compared with placebo in a controlled, randomized, "double-blind" experiment. All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control to determine whether tetrahydrocannabinol had an antiemetic effect. Twenty-two patients entered the study, 20 of whom were evaluable. For all patients an antiemetic effect was observed in 14 of 20 tetrahydrocannabinol courses and in none of 22 placebo courses. For patients completing the study, response occurred in 12 of 15 courses of tetrahydrocannabinol and in none of 14 courses of placebo (P less than 0.001). No patient vomited while experiencing a subjective "high". Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducting vomiting caused by chemotherapeutic agents.
Source: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy
Author(s) Sallan SE, Zinberg NE, Frei E 3d
Journal, Volume, Issue New England Journal of Medicine 1975;293(16):795-797
Major outcome(s) for patients completing the study there were 5 complete responses (no vomiting) and 7 partial responses (50% decrease of vomiting) of overall 15 courses
Indication Cancer chemotherapy; Nausea/vomiting
Medication Delta-9-THC
Route(s) Oral
Dose(s) 3 x 10 or 15 mg/m2 every 4 hours
Duration (days) several days
Participants 84 cancer patients
Design Controlled study
Type of publication
Address of author(s) Sidney Farber Cancer Center, Boston, Massachusetts, USA
Abstract
Anecdotal accounts suggested that smoking marihuana decreases the nausea and vomiting associated with cancer chemotherapeutic agents. Oral delta-9-tetrahydrocannabinol was compared with placebo in a controlled, randomized, "double-blind" experiment. All patients were receiving chemotherapeutic drugs known to cause nausea and vomiting of central origin. Each patient was to serve as his own control to determine whether tetrahydrocannabinol had an antiemetic effect. Twenty-two patients entered the study, 20 of whom were evaluable. For all patients an antiemetic effect was observed in 14 of 20 tetrahydrocannabinol courses and in none of 22 placebo courses. For patients completing the study, response occurred in 12 of 15 courses of tetrahydrocannabinol and in none of 14 courses of placebo (P less than 0.001). No patient vomited while experiencing a subjective "high". Oral tetrahydrocannabinol has antiemetic properties and is significantly better than a placebo in reducting vomiting caused by chemotherapeutic agents.
Source: Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy
